669 related articles for article (PubMed ID: 27366922)
1. Certolizumab pegol for treating axial spondyloarthritis.
Desmarais J; Beier S; Deodhar A
Expert Opin Biol Ther; 2016 Aug; 16(8):1059-64. PubMed ID: 27366922
[TBL] [Abstract][Full Text] [Related]
2. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
Landewé R; Braun J; Deodhar A; Dougados M; Maksymowych WP; Mease PJ; Reveille JD; Rudwaleit M; van der Heijde D; Stach C; Hoepken B; Fichtner A; Coteur G; de Longueville M; Sieper J
Ann Rheum Dis; 2014 Jan; 73(1):39-47. PubMed ID: 24013647
[TBL] [Abstract][Full Text] [Related]
4. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe.
Baraliakos X; Witte T; De Clerck L; Frediani B; Collantes-Estévez E; Katsifis G; VanLunen B; Kleine E; Hoepken B; Bauer L; Goodson N
Rheumatology (Oxford); 2021 Jan; 60(1):113-124. PubMed ID: 32584415
[TBL] [Abstract][Full Text] [Related]
6. Certolizumab pegol: a review of its use in patients with axial spondyloarthritis or psoriatic arthritis.
Dhillon S
Drugs; 2014 Jun; 74(9):999-1016. PubMed ID: 24919863
[TBL] [Abstract][Full Text] [Related]
7. Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol.
Maksymowych WP; Kumke T; Auteri SE; Hoepken B; Bauer L; Rudwaleit M
Arthritis Res Ther; 2021 Oct; 23(1):274. PubMed ID: 34715908
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy.
Marin J; Acosta Felquer ML; Soriano ER
Open Access Rheumatol; 2018; 10():33-41. PubMed ID: 29765257
[TBL] [Abstract][Full Text] [Related]
9. Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.
van der Heijde D; Baraliakos X; Hermann KA; Landewé RBM; Machado PM; Maksymowych WP; Davies OR; de Peyrecave N; Hoepken B; Bauer L; Nurminen T; Braun J
Ann Rheum Dis; 2018 May; 77(5):699-705. PubMed ID: 29343510
[TBL] [Abstract][Full Text] [Related]
10. Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity within and outside the home in patients with axial spondyloarthritis, including nonradiographic axial spondyloarthritis and ankylosing spondylitis.
Osterhaus JT; Purcaru O
Arthritis Res Ther; 2014 Aug; 16(4):R164. PubMed ID: 25099160
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
Callhoff J; Sieper J; Weiß A; Zink A; Listing J
Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis.
Olivieri I; Fanizza C; Gilio M; Ravasio R
Clin Exp Rheumatol; 2016; 34(5):935-940. PubMed ID: 27385374
[TBL] [Abstract][Full Text] [Related]
14. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
[TBL] [Abstract][Full Text] [Related]
15. Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis.
Rudwaleit M; Rosenbaum JT; Landewé R; Marzo-Ortega H; Sieper J; van der Heijde D; Davies O; Bartz H; Hoepken B; Nurminen T; Deodhar A
Arthritis Care Res (Hoboken); 2016 Jun; 68(6):838-44. PubMed ID: 26815944
[TBL] [Abstract][Full Text] [Related]
16. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
[TBL] [Abstract][Full Text] [Related]
17. An appraisal of golimumab in the treatment of severe, active nonradiographic axial spondyloarthritis.
Paccou J; Flipo RM
Drug Des Devel Ther; 2016; 10():2255-62. PubMed ID: 27468228
[TBL] [Abstract][Full Text] [Related]
18. Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction.
Landewé RB; van der Heijde D; Dougados M; Baraliakos X; Van den Bosch FE; Gaffney K; Bauer L; Hoepken B; Davies OR; de Peyrecave N; Thomas K; Gensler LS
Ann Rheum Dis; 2020 Jul; 79(7):920-928. PubMed ID: 32381562
[TBL] [Abstract][Full Text] [Related]
19. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and clinical outcomes of certolizumab pegol treatment in patients with active non-radiographic axial spondyloarthritis: 3-year results from the phase 3 C-axSpAnd study.
van der Heijde D; Gensler LS; Maksymowych WP; Landewé R; Rudwaleit M; Bauer L; Kumke T; Kim M; Auteri SE; Hoepken B; Deodhar A
RMD Open; 2022 Mar; 8(1):. PubMed ID: 35296532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
